Fig. S3


A
Relative levels of lnc173 TSV1 (RPLPO)
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
wild-type
lnc173 KO 4-17
lnc173 KO 4-25
lnc173 KO 12-17
lnc173 KO 12-29
lnc173 KO 12-39
lnc173 KO 12-40
vector control V-3
vector control V-8
vector control V-11
vector control V-12
B
Relative levels of lnc173 TSV2 (RPLPO)
1.2
1.0
0.8
0.6
0.4
0.2
0.0
wild-type
lnc173 KO 4-17
lnc173 KO 4-25
lnc173 KO 12-17
lnc173 KO 12-29
lnc173 KO 12-39
lnc173 KO 12-40
vector control V-3
vector control V-8
vector control V-11
vector control V-12
C
% GFP+
100
90
80
70
60
50
40
30
20
10
0
HIV-1
HIV-1 (1:4)
Mock
wild-type
lnc173 KO 4-17
lnc173 KO 4-25
lnc173 KO 12-17
lnc173 KO 12-29
lnc173 KO 12-39
lnc173 KO 12-40
vector control V-3
vector control V-8
vector control V-11
vector control V-12
D
gMFI (GFP)
4500
4000
3500
3000
2500
2000
1500
1000
500
0
HIV-1
HIV-1 (1:4)
Mock
wild-type
lnc173 KO 4-17
lnc173 KO 4-25
lnc173 KO 12-17
lnc173 KO 12-29
lnc173 KO 12-39
lnc173 KO 12-40
vector control V-3
vector control V-8
vector control V-11
vector control V-12